

# 65

# M

2022/23

## **HALF-YEAR REPORT as at 31 March 2023**

Significant events · Interim Group management report · Consolidated income statements · Consolidated statements of comprehensive income · Consolidated statements of the financial position (balance sheet) · Consolidated statements of changes in equity · Consolidated cash flow statements · Selected notes to the consolidated financial statements · Events after the end of the quarter · Contact · Financial calendar

**B·R·A·I·N**

# ABOUT BRAIN

BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).

Through its own R&D activities, the Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 49.5 million in the fiscal year 2021/22.

# CONTENTS

|                |  |
|----------------|--|
| <b>04 – 05</b> | <b>Significant events</b><br>1 January 2023 to 31 March 2023   |
| <b>06 – 09</b> | <b>Interim Group management report</b><br>1 October 2022 to 31 March 2023  |
| <b>10</b>      | <b>Consolidated income statements [unaudited]</b><br>1 October 2022 to 31 March 2023<br>and for 1 January 2023 to 31 March 2023                  |
| <b>11</b>      | <b>Consolidated statements of comprehensive income [unaudited]</b><br>1 October 2022 to 31 March 2023<br>and for 1 January 2023 to 31 March 2023 |
| <b>12</b>      | <b>Consolidated statements of the financial position (balance sheet) [unaudited]</b><br>31 March 2023  |
| <b>13</b>      | <b>Consolidated statements of changes in equity [unaudited]</b><br>1 October 2022 to 31 March 2023   |
| <b>14</b>      | <b>Consolidated cash flow statements [unaudited]</b><br>1 October 2022 to 31 March 2023  |
| <b>15 – 17</b> | <b>Selected notes to the consolidated financial statements</b><br>1 October 2022 to 31 March 2023  |
| <b>18</b>      | <b>Contact, Financial calendar, disclaimer</b>   |

# SIGNIFICANT EVENTS

1 January 2023 to 31 March 2023

## **Akribion Genomics will prioritize the development of therapeutic applications within its CRISPR technology platform**

BRAIN Biotech AG announced its intent to prioritize the development of the genome-editing activities bundled under the brand name Akribion Genomics on therapeutic applications, including applications in oncology. The mode of action of the nucleases selected for this purpose allows both the targeted cell enrichment and depletion by selective disruption. Due to the novel mode of action the nuclease G-dase E™ (previously termed "BEC") is also primed for applications in therapeutics such as the field of oncology.

## **BRAIN Biotech AG and AMSilk cooperate to develop high-performance bio-based protein fibers**

As part of a strategic collaboration, BRAIN Biotech AG and AMSilk are combining their expertise to drive the development of high-performance fibers for the performance materials market. Bio-fabricated products hold enormous potential as sustainable material solutions for the future. New developments, such as those currently being developed by BRAIN Biotech AG and AMSilk, could revolutionize the performance materials market. Petroleum-based textile fibers made of polyethylene or polyamide, well known to be a main source of microplastics as well as causing the unsustainable disposal of old clothes in landfills.

## **BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères**

BRAIN Biotech AG announced the contract termination with Roquette Frères for the joint development of a natural sweetener solution. BRAIN is convinced of the project's viability and economics of a natural sweetener alternative based on the molecule Brazzein. BRAIN owns the proprietary production technology for the molecule and will look to establish new partnerships on this program

## **BRAIN Biotech AG and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment**

BRAIN Biotech AG announced the signing of a joint development agreement (JDA) with TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA

oncology company committed to more effectively treating cancer using RNA therapeutics. The objective of the JDA is to co-develop a platform technology that combines a Class 2 CRISPR nuclease, the cell-killing G-dase E, developed by BRAIN Biotech's Akribion Genomics unit with TransCode's TTX nucleic acid delivery platform for the treatment of cancer.

TransCode's proprietary TTX platform is designed to enable systemic delivery of targeted nucleic acid-based therapeutics to tumors and metastases. Akribion Genomics' proprietary nuclease is designed to seek out selective genomic characteristics based on the existence of specific RNA biomarkers within target cells. Combining these technologies could unlock the potential of CRISPR-like cell targeting approaches for the treatment of cancer.

# INTERIM GROUP MANAGEMENT REPORT

1 October 2022 to 31 March 2023

## **I. GROUP BASIS AND GENERAL CONDITIONS**

The remarks made in the consolidated financial statements for the financial year ending 30 September 2022 about the Group's basis and general conditions continue to be applicable.

## **II. ECONOMIC AND BUSINESS REPORT**

### **1. Results of operations**

In the first six months of the 2022/2023 financial year, the BRAIN Biotech Group generated revenue of € 27.2 million compared to € 23.3 million in the same period of the previous year, which represents growth of 16.8 %. On an organic basis (in other words, excluding Breatec for the first four months and L.A. Schmitt GmbH for the previous year), revenue rose by 8.2%.

Revenue in the second quarter of 2022/23 amounted to € 13.5 million. This corresponds to an increase of 3.0 % compared to the second quarter of the previous year. Other income decreased by € 0.1 million to € 0.4 million. Total operating performance (revenue, research and development grant revenue, changes in inventories, and other income) in the first six months of the financial year rose by € 3.9 million (16.0 %) year-on-year, from € 24.2 million to € 28.1 million.

BRAIN Biotech AG announced at the Capital Markets Day on 27 February 2023 that it would be changing its reporting structure to three segments plus the holding company with the publication of the half-year figures. This is aligned with the already implemented operational leadership of the Group and further increases transparency for the capital market. The following changes have been made in the segment reporting compared to the consolidated financial statements as at 30 September 2022. The composition of the "BioIndustrial" segment remained unchanged, with the exception of the sale of L.A. Schmitt per 30 September 2022, and was renamed to "BioProducts". From the "BioScience" segment the business unit "BioIncubator" and "BRAIN Biotech Holding" have been excluded and are presented separately going forward. The BioScience segment continues to include the activities of BRAIN Biotech Zwingenberg and AnalytiCon Discovery. The previous year's figures were adjusted accordingly.

Revenue generated by the "BioProducts" segment reported growth of 19.0 %, from € 17.5 million to € 20.9 million, in the reporting period. In the second quarter of the financial year, revenue amounted to € 10.2 million. This corresponds to an increase of € 0.1 million, or 1.0 %, compared with the same quarter of the previous year. Adjusted EBITDA deteriorated from € 2.6 million to € 2.2 million in the first six months. The weaker operating momentum in the

second quarter is mainly due to production interruptions and operational pre-production costs in connection with the commissioning of the second large-scale fermenter at Biocatalysts Ltd. In addition, inflation-driven labour and pre-product costs can only be passed on to end customers with a certain time lag in some cases.

The "BioScience" segment generated revenue of € 6.1 million in the reporting period, corresponding to an increase of € 0.4 million or 6.5 % over the prior-year period. This growth mainly reflected a higher number of contracts signed for Tailor-Made Solutions projects. The adjusted EBITDA deteriorated from € 0.4 million in the same period of the previous year to € -0.0 million. The main drivers for this are increasing investments in personnel and higher other expenses such as increased marketing and sales expenses.

The "BioIncubator" segment generated revenue of € 0.2 million in the reporting period. R&D Grant revenue, generated by research funding from the German Federal Ministry of Education and Research, was slightly higher than the previous year's figure of € 0.1 million at € 0.2 million. The adjusted EBITDA is mainly driven by the ongoing investments into the CRISPR technology platform under the brand name Akribion Genomics and amounts to € -1.5 million in the first six months of the financial year. This is above the previous year's investment in BioIncubator projects of € -1.2 million.

The "BRAIN Biotech Holding" segment mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing and M&A activities. The adjusted EBITDA of the segment amounted to € -1.6 million and is constant at the previous year's level.

The adjusted Group EBITDA deteriorated by € 1.1 million from € 0.2 million in the previous year to € -0.9 million in the first six months of the 2022/23 financial year. This reflects the weaker adjusted EBITDA of € -0.5 million in the second quarter compared to € 0.5 million in the same quarter of the previous year. The main reasons for this were, as described above, start-up costs for the production expansion in fermentation and investments in personnel as well as investments in the BioIncubator.

The net financial result was € -1.1 million compared to € -0.9 million in the same period of the previous year. The increase in financial expenses from € -0.3 million to € -0.6 million is mainly due to interest expenses and the subsequent valuation of the put/call option liability for the acquisition of minority interests in Biocatalysts Ltd. As a result, the consolidated result before taxes deteriorated from € -3.6 million in the same period of the previous year to € -4.6 million in the current period.

Undiluted (basic) and diluted earnings per share during the first six months of the financial year amounted to € -0.22, compared with € -0.18 in the prior-year period.

The following table shows the reconciliation of unadjusted EBITDA to adjusted EBITDA.

| € thousand   | 6M 2022/23    | 6M 2021/22  |
|--|---------------|-------------|
| <b>EBITDA</b>  | <b>-1,349</b> | <b>-725</b> |
| Share-based employee compensation  | -434          | -528        |
| Acquisition and integration costs incurred in the expansion of the BRAIN Biotech Group | 0             | -417        |
| <b>Adjusted EBITDA</b>   | <b>-915</b>   | <b>220</b>  |

## **2. Net assets**

Non-current assets decreased from € 47.6 million as at 30 September 2022 to € 46.5 million as at 31 March 2023 driven by depreciation of fixed assets and amortization of intangible assets.

Current assets decreased from € 30.4 million to € 28.0 million. This reduction is due to lower other current assets resulting from the receipt of the purchase price for the sale of L.A. Schmitt GmbH. In addition, trade receivables were lower compared to the last balance sheet date. Cash and cash equivalents, on the other hand, increased by € 0.7 million from € 8.4 million to € 9.2 million.

Equity decreased from € 34.2 million as at 30 September 2022 to € 29.9 million as at 31 March 2023. This is mainly driven by the negative result for the period. No capital measures were implemented during the reporting period.

The increase in non-current liabilities from € 22.4 million to € 24.2 million is due to an increase in long-term financial liabilities. Current liabilities decreased from € 21.4 million to € 20.4 million. The main reason for this is a net effect of (i) lower trade payables and reduced other liabilities, and (ii) an increase in current financial liabilities, as a result of drawing a short-term loan of € 3.0 million from an existing loan facility in the second quarter of the financial year.

## **3. Financial position**

The Group's gross cash flow in the reporting period amounted to € -2.8 million, compared with € -2.2 million in the previous year.

Cash flow from operating activities deteriorated significantly compared with the same period of the previous year, from € -1.1 million to € -5.6 million. This decline is mainly attributable to the lower EBITDA operating result as well as a higher cash outflow from the change in trade payables and other liabilities.

Cash flow from investing activities in the first six months of the current financial year amounted to € 1.7 million compared to € -6.6 million in the prior-year period. The cash flow from investing activities is positively influenced by the receipt of the purchase price from the sale of L.A. Schmitt GmbH but also includes investments in fixed assets. These investments were lower than in the same period of the previous year.



Cash flow from financing activities, which in the reporting period mainly reflects the cash inflow from increasing financial liabilities, amounted to € 4.6 million compared to € -0.5 million in the previous year.

Compared to 30 September 2022, cash and cash equivalents increased from € 8.4 million to € 9.2 million, which is attributable to the combined aforementioned effects.

### **III. SIGNIFICANT OPPORTUNITIES AND RISKS**

For a presentation of the risk management system and of potential opportunities and risks, please refer to the remarks on pages 94 ff. of the 2021/22 annual report of BRAIN Biotech AG.

Supply chains have proved to be largely stable despite the constraints in global logistics, although long delivery times for certain products have already had a dampening effect on the half-year results in the BioProducts segment due to the tight supply situation. Almost the entire global economy is currently influenced by high inflationary dynamics for raw materials, intermediate products as well as salary and service costs. In some cases, higher salary and input product costs can only be passed on to end customers with a certain time lag. In addition, a general slowdown in economic momentum poses a further challenge for the corporate sector. The general financing situation and financing conditions have deteriorated in particular for growth companies.

Nevertheless, from today's perspective and assuming no unforeseeable extraordinary events, BRAIN Biotech AG does not expect any significant changes compared to the opportunities and risks presented in the 2021/22 annual report.

Risks pursuant to Section 91 (2) of the German Stock Corporation Act (AktG) that might comprise going concern risks for the BRAIN Biotech Group are not identifiable at present.

### **IV. OUTLOOK**

Compared to the outlook report presented on page 93 of the 2021/22 annual report, no significant changes are identifiable concerning the business outlook, apart from those relating to the development of the new genome editing tool of BRAIN Biotech AG. As such, the forecast remains unchanged, except for the elimination of the investments in this project. Despite the continuing strained supply chain situation in selected areas and the high inflationary dynamics, BRAIN Biotech AG is confident that it will be able to achieve the qualitative targets it has set for this financial year.

# CONSOLIDATED INCOME STATEMENTS [UNAUDITED]

1 October 2022 to 31 March 2023 and 1 January 2023 to 31 March 2023

| € thousand  | 6M 2022/23     | 6M 2021/22     | Q2 2022/23    | Q2 2021/22    |
|---|----------------|----------------|---------------|---------------|
| Revenue   | 27,170         | 23,267         | 13,476        | 13,090        |
| Research and development grant revenue                        | 389            | 359            | 147           | 145           |
| Change in inventories of finished goods and work in progress  | 135            | 107            | 762           | 324           |
| Other income  | 399            | 480            | 211           | 219           |
|   | <b>28,093</b>  | <b>24,213</b>  | <b>14,596</b> | <b>13,778</b> |
| <b>Cost of materials</b>                                      |                |                |               |               |
| Cost of raw materials and supplies, and purchased merchandise | -12,455        | -9,428         | -6,808        | -5,601        |
| Cost of purchased services                                    | -540           | -684           | -241          | -350          |
|   | <b>-12,995</b> | <b>-10,112</b> | <b>-7,048</b> | <b>-5,952</b> |
| <b>Personnel expenses</b>                                     |                |                |               |               |
| Wages and salaries  | -9,232         | -8,253         | -4,720        | -4,325        |
| Share-based employee compensation                             | -434           | -528           | -118          | -267          |
| Social security and post-employment benefit costs             | -1,730         | -1,578         | -853          | -788          |
|   | <b>-11,396</b> | <b>-10,359</b> | <b>-5,691</b> | <b>-5,380</b> |
| Other expenses  | -5,051         | -4,467         | -2,503        | -2,524        |
|   | <b>-1,349</b>  | <b>-725</b>    | <b>-646</b>   | <b>-79</b>    |
| <b>EBITDA</b>   |                |                |               |               |
| Depreciation, amortization and impairment                     | -2,216         | -2,058         | -1,108        | -1,081        |
|   | <b>-3,565</b>  | <b>-2,783</b>  | <b>-1,754</b> | <b>-1,160</b> |
| <b>Operating result (EBIT)</b>                                |                |                |               |               |
| Share of profit or loss from equity-accounted investments     | -998           | -1,218         | -581          | -517          |
| Finance income  | 551            | 654            | 547           | 383           |
| Finance costs   | -610           | -290           | -434          | -75           |
|   | <b>-1,057</b>  | <b>-854</b>    | <b>-469</b>   | <b>-209</b>   |
| <b>Pretax result for the reporting period</b>                 |                |                |               |               |
|   | <b>-4,622</b>  | <b>-3,636</b>  | <b>-2,222</b> | <b>-1,369</b> |
| <b>Income tax expense/income</b>                              |                |                |               |               |
| a) Current tax expense  | -166           | -269           | -18           | -132          |
| b) Deferred tax expense (-)/ income (+)                       | 180            | 157            | 88            | 84            |
|   | <b>14</b>      | <b>-112</b>    | <b>71</b>     | <b>-48</b>    |
| <b>Result for the reporting period</b>                        |                |                |               |               |
|   | <b>-4,608</b>  | <b>-3,748</b>  | <b>-2,152</b> | <b>-1,418</b> |
| of which attributable to:                                     |                |                |               |               |
| Non-controlling interests                                     | 189            | 207            | 115           | 179           |
| Shareholders of BRAIN Biotech AG                              | -4,797         | -3,955         | -2,267        | -1,597        |
| Earnings per share, basic (undiluted)                         | -0.22          | -0.18          | -0.10         | -0.07         |
| Number of shares taken as basis                               | 21,847,495     | 21,847,495     | 21,847,495    | 21,847,495    |
| Earnings per share, diluted                                   | -0.22          | -0.18          | -0.10         | -0.07         |
| Number of shares taken as basis                               | 21,847,495     | 21,847,495     | 21,847,495    | 21,847,495    |

# CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

## [UNAUDITED] 1 October 2022 to 31 March 2023 and 1 January 2023 to 31 March 2023

| € thousand   | 6M 2022/23    | 6M 2021/22    | Q2 2022/23    | Q2 2021/22    |
|--|---------------|---------------|---------------|---------------|
| <b>Result for the reporting period</b>                                     | <b>-4,608</b> | <b>-3,748</b> | <b>-2,152</b> | <b>-1,418</b> |
| of which attributable to:  |               |               |               |               |
| Non-controlling interests  | 189           | 207           | 115           | 179           |
| Shareholders of BRAIN Biotech AG   | -4,797        | -3,955        | -2,267        | -1,597        |
| <b>Other comprehensive income:</b>   |               |               |               |               |
| <b>Items that will be reclassified subsequently to profit or loss</b>      |               |               |               |               |
| Differences from the translation of foreign-currency financing instruments | 10            | -95           | -44           | 16            |
| Differences from the translation of foreign operations                     | -183          | 465           | 180           | -66           |
| <b>Other comprehensive income (loss), net</b>                              | <b>-173</b>   | <b>370</b>    | <b>136</b>    | <b>-50</b>    |
| <b>Consolidated total comprehensive income (loss)</b>                      | <b>-4,782</b> | <b>-3,378</b> | <b>-2,016</b> | <b>-1,468</b> |
| of which attributable to:  |               |               |               |               |
| Non-controlling interests  | 180           | 273           | 147           | 226           |
| Shareholders of BRAIN Biotech AG   | -4,961        | -3,652        | -2,162        | -1,695        |

# CONSOLIDATED STATEMENTS OF THE FINANCIAL POSITION (BALANCE SHEET) [UNAUDITED] 31 March 2023

| € thousand  | 31.03.2023    | 30.09.2022    |
|---|---------------|---------------|
| <b>Non-current assets</b>                             |               |               |
| Intangible assets                                     | 15,835        | 16,764        |
| Property, plant and equipment                         | 28,606        | 28,737        |
| Equity-accounted investments                          | 1,903         | 1,938         |
| Other non-current assets                              | 155           | 168           |
|   | <b>46,499</b> | <b>47,608</b> |
| <b>Current assets</b>                                 |               |               |
| Inventories   | 9,666         | 9,661         |
| Trade receivables                                     | 7,244         | 8,036         |
| Other current assets                                  | 1,266         | 3,811         |
| Other financial assets                                | 680           | 435           |
| Cash and cash equivalents                             | 9,156         | 8,443         |
|   | <b>28,012</b> | <b>30,384</b> |
| <b>ASSETS</b>   | <b>74,511</b> | <b>77,992</b> |
| <b>Equity</b>   |               |               |
| Subscribed capital                                    | 21,847        | 21,847        |
| Capital reserves                                      | 93,060        | 92,660        |
| Retained earnings                                     | -89,994       | -85,197       |
| Other reserves  | 164           | 328           |
|   | <b>25,077</b> | <b>29,638</b> |
| Non- controlling interests                            | 4,789         | 4,610         |
| <b>Total equity</b>                                   | <b>29,866</b> | <b>34,248</b> |
| <b>Non-current liabilities</b>                        |               |               |
| Deferred tax  | 3,082         | 3,292         |
| Provisions for post-employment benefits for employees | 1,153         | 1,153         |
| Financial liabilities                                 | 17,674        | 15,435        |
| Other liabilities                                     | 1,689         | 1,709         |
| Deferred income                                       | 644           | 766           |
|   | <b>24,243</b> | <b>22,356</b> |
| <b>Current liabilities</b>                            |               |               |
| Provisions  | 525           | 654           |
| Current tax liabilities                               | 139           | 190           |
| Financial liabilities                                 | 10,985        | 8,437         |
| Prepayments received                                  | 22            | 13            |
| Trade payables  | 4,220         | 6,754         |
| Other liabilities                                     | 2,631         | 3,350         |
| Deferred income                                       | 1,880         | 1,990         |
|   | <b>20,402</b> | <b>21,388</b> |
| <b>EQUITY AND LIABILITIES</b>                         | <b>74,511</b> | <b>77,992</b> |

# CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

## [UNAUDITED] 1 October 2022 to 31 March 2023

| 1 October 2021 to 31 March 2022  | Interests of shareholders of BRAIN Biotech AG |                  |                   |                      |               | Non-controlling interests |               |
|--|---|------------------|-------------------|----------------------|---------------|---------------------------|---------------|
|  | Subscribed capital                            | Capital reserves | Retained earnings | Other reserves       | Total         |                           | Total         |
| € thousand   | Total   |                  |                   | Currency translation |               |                           |               |
| <b>Balance at 30 September 2021</b>  | <b>21,847</b>                                 | <b>95,890</b>    | <b>-79,509</b>    | <b>555</b>           | <b>38,783</b> | <b>3,044</b>              | <b>41,828</b> |
| Total comprehensive income (loss) 01.10.2021 - 31.03.2022  |   |                  | -3,955            | 303                  | -3,652        | 273                       | -3,378        |
| Addition of non-controlling interests part of the acquisition of fully consolidated Group companies  |   |                  |                   |                      |               | 1,621                     | 1,621         |
| Addition of liability from put/call agreement relating to the acquisition of non-controlling interests in fully consolidated Group companies |   | -5,199           |                   |                      | -5,199        |                           | -5,199        |
| Transfers due to employee share scheme   |   | 350              |                   |                      | 350           |                           | 350           |
| <b>Balance at 31 March 2022</b>  | <b>21,847</b>                                 | <b>91,041</b>    | <b>-83,464</b>    | <b>858</b>           | <b>30,282</b> | <b>4,938</b>              | <b>35,221</b> |

| 1 October 2022 to 31 March 2023                           | Interests of shareholders of BRAIN Biotech AG |                  |                   |                      |               | Non-controlling interests |               |
|---|---|------------------|-------------------|----------------------|---------------|---------------------------|---------------|
|   | Subscribed capital                            | Capital reserves | Retained earnings | Other reserves       | Total         |                           | Total         |
| € thousand  | Total   |                  |                   | Currency translation |               |                           |               |
| <b>Balance at 30 September 2022</b>                       | <b>21,847</b>                                 | <b>92,660</b>    | <b>-85,197</b>    | <b>328</b>           | <b>29,638</b> | <b>4,610</b>              | <b>34,248</b> |
| Total comprehensive income (loss) 01.10.2022 - 31.03.2023 |   |                  | -4,797            | -165                 | -4,961        | 180                       | -4,782        |
| Transfers due to employee share scheme                    |   | 399              |                   |                      | 399           |                           | 399           |
| <b>Balance at 31 March 2023</b>                           | <b>21,847</b>                                 | <b>93,060</b>    | <b>-89,994</b>    | <b>164</b>           | <b>25,077</b> | <b>4,789</b>              | <b>29,866</b> |

# CONSOLIDATED CASH FLOW STATEMENTS [UNAUDITED]

1 October 2022 to 31 March 2023

| € thousand  | 6M 2022/23    | 6M 2021/22    |
|---|---------------|---------------|
| Net profit (loss) for the period, after tax   | -4,608        | -3,748        |
| Depreciation and amortization   | 2,216         | 2,058         |
| Deferred tax expense (income)   | -180          | -157          |
| Conversion of deferred income into revenue  | -1,286        | -1,137        |
| Income from the release of provisions and liabilities                                     | -47           | -186          |
| Share of profit or loss from equity-accounted investments                                 | 998           | 1,218         |
| Other non-cash expenses (income)  | 111           | -221          |
| Losses on disposals of intangible assets and property, plant and equipment                | -2            | -27           |
| <b>Gross cash flow</b>  | <b>-2,798</b> | <b>-2,201</b> |
| Change in trade receivables   | 812           | -294          |
| Change in inventories   | -20           | -959          |
| Change in tax assets and liabilities  | -48           | 96            |
| Change in other assets and financial assets   | -745          | -291          |
| Change in trade payables  | -2,399        | 1,072         |
| Change in prepayments received  | 9             | 186           |
| Change in provisions and other liabilities  | -1,158        | -27           |
| Additions from deferred income  | 788           | 1,355         |
| <b>Cash flow from operating activities</b>  | <b>-5,557</b> | <b>-1,062</b> |
| Net cash outflows for acquisitions of companies (less cash and cash equivalents acquired) | 0             | -3,096        |
| Net cash inflows from disposals of companies (less cash and cash equivalents divested)    | 3,040         | 0             |
| Payments to acquire intangible assets   | -8            | -188          |
| Payments to acquire property, plant and equipment   | -1,273        | -2,211        |
| Net proceeds from other non-current assets  | 7             | 7             |
| Investments in equity-accounted shareholdings   | -114          | -1,173        |
| Proceeds from disposal of property, plant and equipment                                   | 41            | 39            |
| <b>Cash flow from investing activities</b>  | <b>1,693</b>  | <b>-6,623</b> |
| Proceeds from borrowings  | 5,792         | 328           |
| Repayments of borrowings  | -1,184        | -840          |
| <b>Cash flow from financing activities</b>  | <b>4,607</b>  | <b>-512</b>   |
| <b>Net change in cash and cash equivalents</b>  | <b>743</b>    | <b>-8,197</b> |
| Cash and cash equivalents at start of reporting period                                    | 8,443         | 24,545        |
| Exchange-rate-related change in cash  | -30           | 93            |
| <b>Cash and cash equivalents at end of reporting period</b>                               | <b>9,156</b>  | <b>16,441</b> |
| <b>Cash flows from operating activities include:</b>                                      |               |               |
| Interest paid   | 274           | 259           |
| Interest received   | 5             | 5             |
| Income taxes paid   | 19            | 73            |
| Income taxes received   | 0             | 0             |

# SELECTED NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS [UNAUDITED]

1 October 2022 to 31 March 2023

## Accounting policies

The Group interim report of BRAIN Biotech AG as at 31 March 2022 was prepared on the basis of IAS 34 (Interim Financial Reporting). All International Financial Reporting Standards (IFRS) that were binding as at the reporting date and had been adopted into European law by the European Commission were applied. The interim consolidated financial statements have not been audited in accordance with Section 317 of the German Commercial Code (HGB), nor have they been reviewed by an auditor.

## Segment reporting

The following changes have been made in the Segment reporting compared to the consolidated financial statements as at 30 September 2022. The composition of the **"BioIndustrial"** segment remained unchanged, with the exception of the sale of L.A. Schmitt per 30 September 2022, and was renamed to **"BioProducts"**. From the **"BioScience"** segment the business unit **"BioIncubator"** and **"BRAIN Biotech Holding"** have been excluded and are presented separately going forward. The BioScience segment continues to include the activities of BRAIN Biotech Zwingenberg and AnalytiCon Discovery. The previous year's figures were adjusted accordingly. The segment results<sup>1</sup> are presented as follows.

| € thousand  | BioProducts   |               | BioScience   |              | BioIncubator  |               | BRAIN Biotech Holding |               | Reconciliation |            | Group         |               |
|---|---------------|---------------|--------------|--------------|---------------|---------------|-----------------------|---------------|----------------|------------|---------------|---------------|
|   | 6M 22/23      | 6M 21/22      | 6M 22/23     | 6M 21/22     | 6M 22/23      | 6M 21/22      | 6M 22/23              | 6M 21/22      | 6M 22/23       | 6M 21/22   | 6M 22/23      | 6M 21/22      |
| <b>Total revenue</b>                                | <b>20,853</b> | <b>17,525</b> | <b>6,145</b> | <b>5,769</b> | <b>175</b>    | <b>0</b>      | <b>0</b>              | <b>0</b>      | <b>-3</b>      | <b>-27</b> | <b>27,170</b> | <b>23,267</b> |
| Of which: Revenue generated with other segments     | 3             | 27            | 0            | 0            | 0             | 0             | 0                     | 0             | -3             | -27        | 0             | 0             |
| Of which: Revenue generated with external customers | 20,849        | 17,498        | 6,145        | 5,769        | 175           | 0             | 0                     | 0             | 0              | 0          | 27,170        | 23,267        |
| R&D grant revenue <sup>2</sup> [external]           | 46            | 46            | 157          | 279          | 186           | 34            | 0                     | 0             | 0              | 0          | 389           | 359           |
| Changes in inventories <sup>3</sup>                 | -12           | 64            | 147          | 43           | 0             | 0             | 0                     | 0             | 0              | 0          | 135           | 107           |
| Other income  | 171           | 118           | 237          | 372          | 0             | 0             | 0                     | 0             | -9             | -10        | 399           | 480           |
| <b>Total operating performance</b>                  | <b>21,059</b> | <b>17,753</b> | <b>6,686</b> | <b>6,463</b> | <b>361</b>    | <b>34</b>     | <b>0</b>              | <b>0</b>      | <b>-13</b>     | <b>-37</b> | <b>28,093</b> | <b>24,213</b> |
| <b>EBITDA</b>                                       | <b>2,131</b>  | <b>2,388</b>  | <b>-180</b>  | <b>198</b>   | <b>-1,470</b> | <b>-1,200</b> | <b>-1,823</b>         | <b>-2,153</b> | <b>-7</b>      | <b>43</b>  | <b>-1,349</b> | <b>-725</b>   |
| <b>Adjusted EBITDA</b>                              | <b>2,165</b>  | <b>2,566</b>  | <b>-9</b>    | <b>389</b>   | <b>-1,470</b> | <b>-1,200</b> | <b>-1,595</b>         | <b>-1,577</b> | <b>-7</b>      | <b>43</b>  | <b>-915</b>   | <b>220</b>    |
| <b>Operating result (EBIT)</b>                      | <b>606</b>    | <b>990</b>    | <b>-871</b>  | <b>-462</b>  | <b>-1,470</b> | <b>-1,200</b> | <b>-1,823</b>         | <b>-2,153</b> | <b>-7</b>      | <b>43</b>  | <b>-3,565</b> | <b>-2,783</b> |
| Finance income                                      |               |               |              |              |               |               |                       |               |                |            | 551           | 654           |
| Result from equity-accounted investments            |               |               |              |              |               |               |                       |               |                |            | -998          | -1,218        |
| Finance costs                                       |               |               |              |              |               |               |                       |               |                |            | -610          | -290          |
| <b>Result before taxes</b>                          |               |               |              |              |               |               |                       |               |                |            | <b>-4,622</b> | <b>-3,636</b> |

- 1 After partial elimination within the segment  
2 Research and development grant revenue  
3 Changes in inventories of finished goods and work in progress

### **Number of employees in the Group<sup>4</sup>**

| Average for the reporting period | 6M 2022/23 | FY 2021/22 |
|----------------------------------|------------|------------|
| <b>Total employees, of which</b> | <b>309</b> | <b>309</b> |
| Salaried employees               | 301        | 284        |
| Industrial employees             | 8          | 24         |

The BRAIN Biotech Group also employees scholarships/grant holders (4, FY 21/22: 1), temporary employees (16, FY 21/22: 12) and trainees (5, FY 21/22: 6).

### **Related party transactions**

During the first six months of the 2022/23 financial year, no new transactions with related parties were concluded that were not already presented in the financial statements as at 30 September 2022, and that had a significant effect on the financial position and performance of the BRAIN Biotech Group.

### **EVENTS AFTER THE END OF THE QUARTER**

#### **BRAIN Biotech AG fully acquires Biocatalysts Ltd.**

BRAIN Biotech AG has acquired the final two minority interests in Biocatalysts Ltd. Biocatalysts is now fully owned by BRAIN Biotech AG and will form the core of the Group's ambitious growth strategy to create a global multi-niche enzyme company.

At the Capital Markets Day on 27 February 2023, BRAIN Biotech AG had announced the bundling of the entire product business under the leadership of Biocatalysts as the OneBio-Products Strategy. In the coming months, the BRAIN Biotech Group will transfer the companies Breatec B.V., Biosun Biochemicals Inc. and WeissBioTech GmbH to Biocatalysts in order to complete the reorganisation of the BioProducts segment.

<sup>4</sup> Excluding the members of the parent company's Management Board and the subsidiaries' managing directors



### **Responsibility statement**

According to the best of our knowledge and in accordance with applicable principles for interim reporting, the interim consolidated financial statements convey a true and fair view of the Group's financial position and performance. The interim Group management report conveys a true and fair view of the development and course of business operations as well as of the Group's position, and appropriately presents the significant opportunities and risks entailed in the Group's future development during the remaining months of the financial year.

Zwingenberg, 25 May 2023

The Management Board



Adriaan Moelker



Michael Schneiders

# CONTACT

You can find the relevant contact persons via this address:

**Investor Relations**  
**ir@brain-biotech.com**  
**+49 (0) 6251/9331-0**

# FINANCIAL CALENDAR

**25.05.2023** Publication of the quarterly statement  
as at 31.03.2023 (6M)

---

**30.08.2023** Publication of the quarterly statement  
as at 30.06.2023 (9M)

---

**17.01.2024** Publication of the annual report  
as at 30.09.2023 (12M)

---

**28.02.2024** Publication of the quarterly statement  
as at 31.12.2023 (3M)

---

**12.03.2024** Annual General Meeting

## Disclaimer

This interim report might contain certain forward-looking statements that are based on current assumptions and forecasts made by the management of the BRAIN Biotech Group and other currently available information. Various known and unknown risks and uncertainties as well as other factors can cause the company's actual results, financial position, development or performance to diverge significantly from the estimates provided here. BRAIN Biotech AG does not intend and assumes no obligation of any kind to update such forward-looking statements and adapt them to future events or developments. The interim report can include information that does not form part of accounting regulations. Such information is to be regarded as a supplement to, but not a substitute for, information prepared according to IFRS. Due to rounding, it is possible that some figures in this and other documents do not add up precisely to the stated sum, and that stated percentages do not reflect the absolute figures to which they relate. This document is a translation of a document originally prepared in German. Where differences occur, precedence is given to the original German version.

Publication date: 25 May 2023

Published by:

**B·R·A·I·N**

BRAIN Biotech AG

Darmstädter Straße 34 – 36

64673 Zwingenberg · Germany

phone +49 (0) 62 51 / 9331-0

fax +49 (0) 62 51 / 9331-11

email [public@brain-biotech.com](mailto:public@brain-biotech.com)

website [www.brain-biotech.com](http://www.brain-biotech.com)